ArticleBMC infectious diseases2026
Risk factors and clinical characteristics of fulminant Mycoplasma pneumoniae pneumonia in children: a retrospective case‒control study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early Risk Stratification for Subsequent Small Airway Dysfunction in Hospitalized Children withChildren (Basel, Switzerland) · 2026Article
- Machine learning based development of an early diagnosis signature for distinguishing hospitalized pediatric human respiratory syncytial virus infection from mycoplasma pneumonia.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFulminant Mycoplasma pneumoniae pneumonia (FMPP) represents a life-threatening progression of typical Mycoplasma pneumoniae pneumonia (MPP) in pediatric patients. This study aimed to identify the risk factors and clinical characteristics associated with FMPP complicated by respiratory failure in children, thereby facilitating early recognition and timely intervention.
methodsA retrospective case–control study was conducted involving 66 children with FMPP and 217 children with non-fulminant Mycoplasma pneumoniae pneumonia (NFMPP) who were admitted to the Department of Respiratory Medicine and the Intensive Care Unit of the Children’s Hospital Affiliated with Chongqing Medical University between January and December 2023. Cox regression analysis was performed to identify independent risk factors for FMPP. Propensity score matching (PSM) was applied to balance baseline risk factors, followed by a comparative analysis of clinical characteristics between the matched FMPP group (n = 62) and the matched NFMPP group (n = 116).
resultsWheezing, a Mycoplasma pneumoniae load ≥ 1.7 × 10⁷ copies/mL, and pulmonary consolidation were independently associated with FMPP, whereas concomitant Epstein-Barr virus infection and β-lactam treatment for ≥ 3 days were inversely associated. After PSM, children with FMPP more frequently presented with fine crackles and wheezing and had higher rates of atelectasis and neurological complications. Compared with NFMPP cases, FMPP was characterized by increased peripheral blood and bronchoalveolar lavage neutrophil proportions and elevated liver enzyme levels, along with lower fibrinogen, total protein, albumin, and interferon-γ levels. In multivariable analysis, fine crackles, peripheral blood neutrophil percentage, and fibrinogen level remained independently associated with FMPP. Clinically, children with FMPP required more frequent escalation to second-line antimycoplasma therapy, β-lactam antibiotics, and glucocorticoids and experienced longer hospital stays; however, all patients recovered without mortality.
conclusionWheezing, a high Mycoplasma pneumoniae load, and pulmonary consolidation are independent risk factors for FMPP, whereas Epstein-Barr virus coinfection and early β-lactam therapy may mitigate disease progression. Although FMPP is characterized by severe systemic inflammation and multiorgan involvement, prompt and appropriate management can lead to favourable clinical outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.